In Tuesday’s Wall Street session, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares traded at $17.19, down -0.41% from the previous session.
TEVA stock price is now 9.60% away from the 50-day moving average and -1.98% away from the 200-day moving average. The market capitalization of the company currently stands at $19.70B.
With the price target of $25, Truist recently initiated with Buy rating for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA). On May 12, 2025, JP Morgan Upgraded its previous ‘Neutral’ rating to ‘Overweight’ on the stock keeping its target price maintained at $23, while ‘Argus’ rates the stock as ‘Buy’
In other news, Shields Matthew, Officer bought 6,206 shares of the company’s stock on Jun 03 ’25. The stock was bought for $105,628 at an average price of $17.02. An SEC document containing details of the transaction can be found on the SEC’s website. On May 08 ’25, See “Remarks” Sabag Mark sold 337,915 shares of the business’s stock. A total of $6,097,304 was realized by selling the stock at an average price of $18.04. This leaves the insider owning 150,996 shares of the company worth $2.6 million. A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $12.47 and a high of $22.80. As of last week, the company has a debt-to-equity ratio of 2.71, a current ratio of 1.03, and a quick ratio of 0.74.
The net profit margin was -7.76% and return on equity was -18.98% for TEVA. The company reported revenue of $3.89 billion for the quarter, compared to $3.82 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.89 percent.
